SAN FRANCISCO--(BUSINESS WIRE)--Oct. 27, 2009--
Urigen Pharmaceuticals, Inc. (OTCBB:URGP), focused on the development of
treatments for urologic disorders and pain, announces a presentation at
its offices on October 30, 2009 at 2PM PST. The slides presented will be
posted to its website at www.urigen.com
after the close of trading that day.
“Interstitial Cystitis/Painful Bladder Syndrome is an important unmet
medical need,” said Urigen CEO William J. Garner, MD. “As part of IC
Awareness Week, Urigen would like to do its part to offer a presentation
based on the work of its scientific founder, Lowell Parsons, MD.”
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company
dedicated to the development and commercialization of therapeutic
products for urological disorders. Urigen's two lead programs target
significant unmet medical needs and major market opportunities in
urology. Urigen's URG101, a proprietary combination of approved drugs
that is instilled into the bladder, targets painful bladder syndrome,
which affects approximately 10.5 million men and women in North America.
Urigen's URG301, a proprietary dosage form of an approved drug that is
locally delivered to control urinary urgency, targets acute urgency in
females diagnosed with an overactive bladder, another major unmet need
that is insufficiently managed by presently available overactive bladder
drugs. For further information, please visit Urigen's website at http://www.urigen.com.
This press release may contain forward-looking statements. These
statements may be identified by the use of forward-looking terminology
such as "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "might," "plan," "potential," "predict,"
"should," or "will," or the negative thereof or other variations thereon
or comparable terminology. Urigen has based these forward-looking
statements on current expectations, assumptions, estimates and
projections. While Urigen believes that these expectations, assumptions,
estimates and projections are reasonable, such forward-looking
statements are only predictions and involve known and unknown risks and
uncertainties, many of which are beyond its control. Given these risks
and uncertainties, investors and security holders are cautioned not to
place undue reliance on such forward-looking statements. Urigen does not
undertake any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect
future events or developments.
Source: Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc.
Martin E. Shmagin, CFO, 415-781-0350